PharmAbcine Inc. - Laporan Laba Rugi (TTM)

PharmAbcine Inc.
KR ˙ KOSDAQ ˙ KR7208340000
Laporan Laba Rugi (TTM)

Laporan Laba Rugi PharmAbcine Inc. menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.

Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.

2020
09-30
2020
12-31
2021
03-31
2021
06-30
2021
09-30
2021
12-31
2022
03-31
2022
06-30
2022
09-30
2022
12-31
2023
03-31
2023
06-30
2023
09-30
2023
12-31
2024
03-31
2024
06-30
2024
09-30
2024
12-31
2025
03-31
2025
06-30
Revenue 10 60 110 110 100 68 45 55 90 207 185 175 146 75 113 113 744 3,886 5,741 7,878
Change (%) 498.18 83.59 0.00 -9.11 -32.18 -33.86 22.11 64.74 129.35 -10.45 -5.35 -16.57 -48.69 50.17 0.00 561.07 422.13 47.76 37.22
% of Revenue 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost Of Sales 1 1 2 3 5 5 7 7 5 5 1 62 67 129 129 67 624 3,437 5,228 6,899
Change (%) 44.00 67.00 14.41 92.00 -2.92 49.79 -1.03 -33.64 0.98 -75.53 5,364.25 8.25 91.77 0.00 -47.93 832.47 450.81 52.13 31.97
% of Revenue 9.09 2.19 1.99 2.28 4.81 6.89 15.59 12.64 5.09 2.24 0.61 35.35 45.87 171.44 114.17 59.44 83.84 88.45 91.06 87.58
Gross Operating Profit 9 59 108 107 95 63 38 48 85 202 184 113 79 -54 -16 46 120 449 513 979
Change (%) 543.59 83.96 -0.29 -11.46 -33.66 -40.04 26.38 78.98 136.24 -8.95 -38.44 -30.14 -167.72 -70.22 -386.33 163.32 273.28 14.34 90.73
% of Revenue 90.91 97.81 98.01 97.72 95.19 93.11 84.41 87.36 94.91 97.76 99.39 64.65 54.13 -71.44 -14.17 40.56 16.16 11.55 8.94 12.42
SG&A 4,900 5,268 4,367 4,561 4,555 4,318 4,405 574 4,159 4,267 4,442 7,791 3,955 3,890 3,326 3,140 3,058 4,139 4,337 3,128
Change (%) 7.51 -17.10 4.43 -0.14 -5.19 2.01 -86.97 624.61 2.59 4.10 75.38 -49.23 -1.66 -14.48 -5.59 -2.63 35.37 4.79 -27.88
% of Revenue 48,997.52 8,806.57 3,976.81 4,153.02 4,562.87 6,378.68 9,837.68 1,049.80 4,617.46 2,065.41 2,400.91 4,448.82 2,707.27 5,188.54 2,954.80 2,789.60 410.88 106.53 75.54 39.70
R&D 16,066 20,183 24,410 28,750 36,609 33,686 32,883 33,567 20,203 18,928 15,462 7,472 9,829 7,809 5,746 5,663 4,861 5,019 4,510 5,459
Change (%) 25.63 20.94 17.78 27.33 -7.98 -2.38 2.08 -39.81 -6.31 -18.31 -51.68 31.55 -20.55 -26.42 -1.44 -14.17 3.27 -10.14 21.04
% of Revenue 160,662.80 33,741.20 22,227.55 26,179.67 36,675.47 49,759.64 73,436.60 61,390.50 22,428.78 9,161.79 8,357.06 4,266.71 6,727.80 10,417.05 5,104.44 5,030.70 653.16 129.18 78.56 69.30
OpEx 20,786 25,567 28,847 33,435 41,308 38,290 37,628 34,596 24,758 23,497 20,205 15,538 14,137 12,177 9,546 9,215 8,910 12,926 14,423 15,940
Change (%) 23.00 12.83 15.91 23.55 -7.31 -1.73 -8.06 -28.44 -5.09 -14.01 -23.10 -9.02 -13.86 -21.60 -3.47 -3.31 45.07 11.58 10.52
% of Revenue 207,859.10 42,741.12 26,267.68 30,445.89 41,383.34 56,560.31 84,032.00 63,272.19 27,485.08 11,373.13 10,920.59 8,872.66 9,676.14 16,243.54 8,480.23 8,186.13 1,197.28 332.66 251.21 202.33
Operating Income -20,776 -25,507 -28,737 -33,325 -41,208 -38,222 -37,583 -34,541 -24,668 -23,290 -20,020 -15,363 -13,991 -12,102 -9,434 -9,103 -8,166 -9,040 -8,681 -8,062
Change (%) 22.77 12.66 15.97 23.65 -7.25 -1.67 -8.09 -28.58 -5.59 -14.04 -23.26 -8.93 -13.50 -22.05 -3.51 -10.29 10.71 -3.97 -7.14
% of Revenue -207,759.10 -42,641.13 -26,167.68 -30,345.89 -41,283.34 -56,460.31 -83,932.00 -63,172.21 -27,385.09 -11,273.13 -10,820.59 -8,772.66 -9,576.14 -16,143.55 -8,380.24 -8,086.13 -1,097.28 -232.66 -151.21 -102.33
Interest Expense -7,535 -7,425 -7,503 -7,060 -5,944 -4,355 -2,419 -1,491 -731 -509 -785 -1,370 -1,138 -1,439 -1,459 -110 -77 -73
Change (%) -1.45 1.04 -5.90 -15.82 -26.73 -44.45 -38.37 -50.96 -30.45 54.25 -16.91 26.40 1.39 -92.48 -29.59 -4.84
% of Revenue -75,346.11 -12,413.12 -6,832.00 -6,429.24 -5,954.56 -6,433.24 -5,403.30 -2,727.06 -811.82 -246.17 -424.03 -1,827.19 -1,011.03 -1,277.91 -196.00 -2.82 -1.34 -0.93
Net Income -22,646 -30,678 -41,339 -43,332 -46,929 -44,033 -34,418 -33,487 -24,054 -30,548 -27,858 -24,369 -24,394 -14,247 -11,384 -8,380 -6,196 -4,924 -4,151 -3,809
Change (%) 35.47 34.75 4.82 8.30 -6.17 -21.84 -2.71 -28.17 27.00 -8.81 -12.52 0.10 -41.60 -20.09 -26.39 -26.06 -20.53 -15.69 -8.24
% of Revenue -226,457.00 -51,285.28 -37,643.57 -39,457.89 -47,014.95 -65,043.78 -76,864.49 -61,243.50 -26,703.15 -14,786.41 -15,056.63 -13,915.86 -16,696.73 -19,004.64 -10,112.61 -7,443.96 -832.56 -126.72 -72.30 -48.35

Source: Capital IQ

Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista